Detection of the colorectal carcinoma liver metastases with magnetic resonance after intravenous application of hepatocellular contrast agent (Gd-EOB-DTPA), comparison with the intraoperative ultrasound;Detekce metastáz kolorektálního karcinomu v játrech: Porovnání magnetické rezonance s podán_avim hepatocelulární kontrastní látky (GD-EOB-DTPA) a peroperační ultrasonografie

Ceska Radiologie

Volumn 62, Issue 1, 2008, Pages 60-65

  Ferda, Jiří ^a   Mírka, Hynek ^a   Kastner, Jan ^a   Ohlídalová, Kristýna ^a   Ferdová, Eva ^a   Vondráková, Renata ^a   Kreuzberg, Boris ^a   Třeška, Vladislav ^a   Skalický, Tomáš ^a   Sutnar, Alan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal carcinoma; Gadoxetic acid; Gd EOB DTPA; Hepatobiliary contrast agents; Intraoperative ultrasound; Liver metastases; Magnetic resonance imaging

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FEMALE; GASTROINTESTINAL SURGERY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER HEMANGIOMA; LIVER METASTASIS; MALE; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY;

EID: 41749120559     PISSN: 12107883     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT Jr. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987; 162: 211-216.
2. Jung G, Heindel W, Krahe T, Kugel H, Walter C, Fischbach R, Klaus H, Lackner K. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs. Magn Reson Imaging 1998; 16(8): 925-931.
3. Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ, Weinmann HJ. Gadoliniumethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 1997; 7: 126-132.
4. Schmitz SA, Wagner S, Schuhmann-Giampieri G, Krause W, Wolf KJ. A prototype liver - specific contrast medium for CT: preclinical evaluation of gadoxetic acid disodium, or Gd-EOB-DTPA. Radiology. 1997; 202(2): 407-412.
5. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ, Strotzer M, Taupitz M, Vogl TJ. European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
6. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR maging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478.
7. Patel NA, Rob MS. Utility of intraoperative liver ultrasound. Surg Clin North Am 2004; 84: 513-524. Review.
8. Takigawa Y, Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Makuuchi M. New lesions detected by intraoperative ultrasound during liver resection for hepatocellular carcinoma. Ultrasound Med Biol 2001; 27: 151-156.
9. Schmitt-Willich H, Brehm M, Ewers CL, Michl G, Muller-Fahrnow A, Petrov O, Platzek J, Raduchel B, Sulzle D. Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA. Inorg Chem 1999 Mar 22; 38: 1134-1144.
10. Žižka J, Klzo L, Ferda J, Mrklovský M, Bukač J. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62: 186-191.
11. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14: 559-578.
12. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR Imaging in Patients with suspected Liver Metastases: Value of Liver-specific Contrast Agent Gd-EOB-DTPA. Magn Reson Med Sci 2007; 6: 43-52.
13. Petersein J, Saini S, Weissleder R. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Magn Reson Imaging Clin N Am 1996; 4: 53-60.
14. Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S, Modder U. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006; 47: 15-23.
15. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver specific contrast agent: US multicenter phase III study. Radiology 2005; 237: 89-98.
16. Kim YK, Lee JM, Kim CS, Cchung GH, Kim CY, Kim IH. Detection of liver metastases: comparison of gadobenat -imeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MRI imaging versus superparamagnetic iron oxide-enhanced MR imaging.Eur Radiol 2005; 15: 220-228.
17. Del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: gadobenat dimeglumine-enhanced and ferrumoxides-enhanced MR imaging examinations. Radiology 2002; 225: 766-772.